Journal of the American College of Cardiology · Nov 19, 2026

Lipid-Lowering Strategies in the Era of Early Atherosclerosis Detection: 2026 ACC Scientific Statement

By Greenland P, Badimon L, Bittner V et al.

Atherosclerotic cardiovascular disease (ASCVD) begins early in life, driven in large part by cumulative exposure to low-density lipoprotein cholesterol and other atherogenic lipoproteins. Contemporary evidence from epidemiologic cohorts, genetic studies, imaging studies, and lipid-lowering trials supports a paradigm of earlier identification and more sustained treatment of individuals at increased ASCVD risk. This American College of Cardiology Scientific Statement reviews the rationale for early adoption of lipid-lowering strategies, with emphasis on lifetime lipid burden, inherited and acquired risk enhancers, and the role of subclinical atherosclerosis assessment. Available clinical trial data suggest that greater absolute low-density lipoprotein cholesterol reduction and longer treatment duration can reduce ASCVD events, even though direct evidence remains limited in younger populations at low short-term risk. Atherosclerosis detected by imaging may identify individuals whose ASCVD risk is underestimated by traditional calculators, but optimal strategies for screening, treatment thresholds, safety, adherence, cost-effectiveness, and value require further study. Clinicians should integrate estimated short- and long-term risk, lipid burden, risk enhancers, imaging findings when appropriate, and patient preferences to guide individualized, shared decision making to reduce lifetime ASCVD risk.

doi.org/10.1016/j.jacc.2026.10.067PubMed 43062386Interventions

AgingResearch.News